Intellia Therapeutics Inc (NASDAQ: NTLA) on Tuesday, plunged -3.13% from the previous trading day, before settling in for the closing price of $10.05. Within the past 52 weeks, NTLA’s price has moved between $9.65 and $34.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 4.71%. The company achieved an average annual earnings per share of 2.18%. With a float of $99.79 million, this company’s outstanding shares have now reached $101.80 million.
Let’s determine the extent of company efficiency that accounts for 526 employees. In terms of profitability, gross margin is 82.41%, operating margin of -1247.99%, and the pretax margin is -1212.19%.
Intellia Therapeutics Inc (NTLA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Intellia Therapeutics Inc is 2.02%, while institutional ownership is 92.46%. The most recent insider transaction that took place on Jan 03 ’25, was worth 16,711. In this transaction VP, Chief Accounting Officer of this company sold 1,372 shares at a rate of $12.18, taking the stock ownership to the 45,640 shares. Before that another transaction happened on Jan 03 ’25, when Company’s EVP, General Counsel sold 7,074 for $12.18, making the entire transaction worth $86,161. This insider now owns 74,497 shares in total.
Intellia Therapeutics Inc (NTLA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.18% per share during the next fiscal year.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Intellia Therapeutics Inc (NTLA) is currently performing well based on its current performance indicators. A quick ratio of 6.73 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.33 in the next quarter and is forecasted to reach -5.15 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Looking closely at Intellia Therapeutics Inc (NASDAQ: NTLA), its last 5-days average volume was 3.74 million, which is a jump from its year-to-date volume of 3.36 million. As of the previous 9 days, the stock’s Stochastic %D was 7.58%. Additionally, its Average True Range was 0.83.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 1.03%, which indicates a significant decrease from 3.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.49% in the past 14 days, which was higher than the 71.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.73, while its 200-day Moving Average is $20.47. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $10.22. Second resistance stands at $10.71. The third major resistance level sits at $11.03. If the price goes on to break the first support level at $9.42, it is likely to go to the next support level at $9.10. Now, if the price goes above the second support level, the third support stands at $8.61.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
Market capitalization of the company is 991.50 million based on 101,849K outstanding shares. Right now, sales total 36,280 K and income totals -481,190 K. The company made 9,110 K in profit during its latest quarter, and -135,710 K in sales during its previous quarter.
